Fresenius Medical Care, the largest kidney dialysis provider in the United States, said it plans to begin administering the intravenous treatments nationwide this week at facilities dedicated to handling Covid-19 patients or during shifts set up for only those patients.
Timely use of the treatment could help reduce hospital admissions, said Mary Dittrich, the dialysis company’s chief medical officer.Some doctors have questioned the efficacy of the new treatments, which in any case are complicated to use, taking two hours to infuse and monitor a patient. Nearly 500,000 people in the United States are on dialysis, a process of mechanically cleaning blood usually done three times a week. Diabetes is the most common cause of kidney failure.Pharmaceuticals Inc.’s cocktail of casirivimab and imdevimab have the U.S. government’s emergency authorization for non-hospitalized Covid-19 patients who are at high risk of becoming severely ill.St.
The federal government has multi-million dollar contracts with both Lilly and Regeneron for supplies of the antibody therapies.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.